Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection Versus Amiodarone in Subjects With Recent Onset Atrial Fibrillation

NCT00668759 is registered in ClinicalTrials.gov with Advanz Pharma as lead sponsor.

NCT NCT00668759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00668759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection Versus Amiodarone in Subjects With Recent Onset Atrial Fibrillation
Lead sponsor
Advanz Pharma
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2008
Completion date
November 30, 2009
Enrollment
254 (actual)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation